利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

26 条记录 (耗时 0.022 秒)

    Non-Anilinic Derivatives Of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators
    4.
    发明申请
    Non-Anilinic Derivatives Of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators 审中-公开
    异噻唑啉-3（2H） - 二氧化铅的非苯胺衍生物作为肝X受体调节剂

    公开(公告)号：US20080139616A1

    公开(公告)日：2008-06-12

    申请号：US11813458

    申请日：2006-01-09

    申请人： Lanna Li ,  Marianne Swanson ,  Kay Brickmann

    发明人： Lanna Li ,  Marianne Swanson ,  Kay Brickmann

    IPC分类号： A61K31/4523 ,  C07D221/00 ,  A61K31/425 ,  A61P9/00 ,  C07D275/02

    CPC分类号： C07D275/03 ,  C07D417/14

    摘要： The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.

    摘要翻译： 本发明涉及式（I）的某些新化合物，其用于制备这些化合物，用于调节核激素受体肝X受体（LXR）α（NR1H3）和/或β（NR1H2）和在 治疗和/或预防包括心血管疾病如动脉粥样硬化的临床病症; 炎性疾病，阿尔茨海默病，与胰岛素抵抗相关的脂质紊乱（血脂异常），2型糖尿病和代谢综合征的其他表现，其治疗用途的方法和含有它们的药物组合物。

    Mchir antagonists
    8.
    发明申请
    Mchir antagonists 审中-公开

    公开(公告)号：US20060247439A1

    公开(公告)日：2006-11-02

    申请号：US10520372

    申请日：2003-07-04

    申请人： Asim Ray ,  Emma Evertsson ,  Anna Stina Linusson Jonsson ,  Pernilla Sandberg ,  Tord Ingiiardt ,  Anette Svensson ,  Kay Brickmann

    发明人： Asim Ray ,  Emma Evertsson ,  Anna Stina Linusson Jonsson ,  Pernilla Sandberg ,  Tord Ingiiardt ,  Anette Svensson ,  Kay Brickmann

    IPC分类号： A61K31/4709 ,  A61K31/4706 ,  C07D409/02 ,  C07D405/02 ,  C07D401/02

    CPC分类号： C07D215/38 ,  C07D401/12 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12

    摘要： The present invention provides compounds of formula (I), wherein R1 represents a C1-4 alkoxy group optionally substituted by one or more fluoro or a C1-4alkyl group optionally substituted by one or more fluoro; n represents 0 or 1; R2 represents a C1-4alkyl group optionally substituted by one or more fluoro or a C1-4alkoxy group optionally substituted by one or more fluoro; m represents 0 or 1; R3 represents H or a C1-4alkyl group; L1 represents an alkylene chain (CH2)r in which r represents 2 or 3 or L1 represents a cyclohexyl group wherein the two nitrogens bearing R3 and R4, respectively, are linked to the cyclohexyl group either via the 1,3 or the 1,4 positions of the cyclohexyl group or L1 represents a cyclopentyl group wherein the two nitrogens bearing R3 and R4, respectively, are linked to the cyclopentyl group via the 1,3 position of the cyclopentyl group and additionally when R5 represents 9,10-methanoanthracen-9(10H)-yl the group -L1-N(R4)— together represents a piperidyl ring which is linked to L2 through the piperidinyl nitrogen and to N—R3 via the 4 position of the piperidyl ring with the proviso that when R5 represents 9,10-methanoanthracen-9(10H)-yl then r is only 2; R4 represents H or a C1-4alkyl group optionally substituted by one or more of the following: an aryl group or a heteroaryl group; L2 represents a bond or an alkylene chain (CH2), in which s represents 1, 2 or 3 wherein the alkylene chain is optionally substituted by one or more of the following: a C1-4alkyl group, phenyl or heteroaryl; R5 represents aryl, a heterocyclic group or a CH3-8cycloalkyl group which is optionally fused to a phenyl or to a heteroaryl group; as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts, thereof; with provisos, processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders and to pharmaceutical compositions containing them.